NASDAQ:EDIT

Editas Medicine (EDIT) Stock Forecast, Price & News

$6.92

-0.19 (-2.67%)

(As of 09/28/2023 ET)

Compare

Today's Range: $6.84
▼
$7.05
50-Day Range: $6.92
▼
$9.31
52-Week Range: $6.33
▼
$14.23

Volume: 1.21 million shs
Average Volume: 1.81 million shs
Market Capitalization: $564.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.57

Editas Medicine MarketRank™ Forecast

Analyst Rating: Hold
2.43 Rating Score
Upside/Downside: 125.0% Upside
$15.57 Price Target
Short Interest: Bearish
18.60% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: 0.29
Based on 11 Articles This Week
Insider Trading: Selling Shares
$46,111 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.55) to ($2.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

709th out of 969 stocks

Biological Products, Except Diagnostic Industry

114th out of 161 stocks

3.2

Analyst's Opinion

Consensus Rating
Editas Medicine has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 7 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $15.57, Editas Medicine has a forecasted upside of 125.0% from its current price of $6.92.
Amount of Analyst Coverage
Editas Medicine has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
18.60% of the outstanding shares of Editas Medicine have been sold short.
Short Interest Ratio / Days to Cover
Editas Medicine has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Editas Medicine has recently increased by 4.69%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Editas Medicine does not currently pay a dividend.
Dividend Growth
Editas Medicine does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Editas Medicine has received a 77.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Editas Medicine is -0.57.

2.4

News and Social Media Coverage

News Sentiment
Editas Medicine has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Editas Medicine this week, compared to 3 articles on an average week.
Search Interest
Only 12 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.
MarketBeat Follows
24 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,111.00 in company stock.
Percentage Held by Insiders
Only 2.20% of the stock of Editas Medicine is held by insiders.
Percentage Held by Institutions
76.61% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Editas Medicine are expected to decrease in the coming year, from ($2.55) to ($2.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Editas Medicine is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Editas Medicine is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Editas Medicine has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Price History

30 days | 90 days | 365 days | Advanced Chart

EDIT Stock News Headlines

September 25, 2023 | marketbeat.com

Are Gene Therapy Stocks The Market's Next Big Winners? (EDIT)

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

September 26, 2023 | seekingalpha.com

Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript)

September 28, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 25, 2023 | finance.yahoo.com

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

September 23, 2023 | finance.yahoo.com

1 Gene Editing Stock to Buy Now, and 1 to Sell

September 23, 2023 | americanbankingnews.com

Zacks Research Weighs in on Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)

September 19, 2023 | americanbankingnews.com

Editas Medicine (NASDAQ:EDIT) versus Autolus Therapeutics (NASDAQ:AUTL) Critical Survey

September 15, 2023 | ca.finance.yahoo.com

Editas Medicine, Inc. (EDIT)

September 28, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 11, 2023 | seekingalpha.com

Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill Presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

September 7, 2023 | seekingalpha.com

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo Securities Healthcare Conference Call Transcript

September 7, 2023 | finance.yahoo.com

Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?

August 30, 2023 | markets.businessinsider.com

Cantor Fitzgerald Keeps Their Buy Rating on Editas Medicine (EDIT)

August 7, 2023 | markets.businessinsider.com

Truist Financial Sticks to Their Buy Rating for Editas Medicine (EDIT)

August 4, 2023 | markets.businessinsider.com

RBC Capital Sticks to Its Hold Rating for Editas Medicine (EDIT)

August 3, 2023 | msn.com

Chardan Capital Maintains Editas Medicine (EDIT) Buy Recommendation

July 24, 2023 | finance.yahoo.com

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

July 23, 2023 | seekingalpha.com

Editas Medicine: Progress, Pitfalls, And Future Expectations

July 17, 2023 | finance.yahoo.com

EDIT - Editas Medicine, Inc.

July 14, 2023 | msn.com

Editas Medicine Bolsters Cash Position Amidst Slow And Steady Progress

July 7, 2023 | nasdaq.com

Editas Medicine (EDIT) Price Target Increased by 5.56% to 13.68

June 26, 2023 | markets.businessinsider.com

SVB Securities Sticks to Its Hold Rating for Editas Medicine (EDIT)

June 22, 2023 | markets.businessinsider.com

Robert W. Baird Remains a Buy on Editas Medicine (EDIT)

June 20, 2023 | finance.yahoo.com

After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?

June 16, 2023 | msn.com

Editas Medicine down 6%, prices $125M offering

June 16, 2023 | marketwatch.com

Editas Medicine Shares Fall 15% on Pricing of Secondary Stock Offering

June 16, 2023 | markets.businessinsider.com

Editas Medicine Plunges After Pricing 12.5 Mln Share Offering

See More Headlines

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings: 8/02/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EDIT
CUSIP: N/A
CIK: 1650664
Web: www.editasmedicine.com
Phone: (617) 401-9000
Fax: N/A
Employees: 226
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.57
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +124.7%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-220,430,000.00
Net Margins: -1,065.39%
Pretax Margin: -1,065.39%
Return on Equity: -55.14%
Return on Assets: -40.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.09
Quick Ratio: 8.09

Sales & Book Value

Annual Sales: $19.71 million
Price / Sales: 28.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.25 per share
Price / Book: 1.32

Miscellaneous

Outstanding Shares: 81,630,000
Free Float: 79,837,000
Market Cap: $565.70 million
Optionable: Optionable
Beta: 1.79

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Gilmore O'Neill (Age 59)
Pres, CEO & Director
Comp: $815.37k

Dr. Bruce E. Eaton Ph.D. (Age 69)
Exec. VP, CTO & Chief Bus. Officer
Comp: $786.23k

Dr. Baisong Mei M.D.
Ph.D., Sr. VP & Chief Medical Officer

Dr. Feng Zhang Ph.D.
Co-Founder & Scientific Advisory Board Member

Dr. George McDonald Church Ph.D. (Age 69)
Co-Founder & Scientific Advisory Board Member

Dr. J. Keith Joung M.D.
Ph.D., Co-Founder & Scientific Advisory Board Member

Dr. David R. Liu Ph.D.
Co-Founder & Scientific Advisory Board Member

Mr. Erick J. Lucera C.F.A. (Age 55)
C.P.A., CFA, CPA, CFO & Exec. VP

Mr. Harry R. Gill III (Age 62)
Sr. VP of Operations

Dr. Linda C. Burkly Ph.D.
Exec. VP & Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.
What is Editas Medicine's stock price forecast for 2023?: 13 brokerages have issued 12 month price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.57 in the next year. This suggests a possible upside of 124.7% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.
How have EDIT shares performed in 2023?: Editas Medicine's stock was trading at $8.87 at the beginning of the year. Since then, EDIT stock has decreased by 21.9% and is now trading at $6.93.
View the best growth stocks for 2023 here.
When is Editas Medicine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our EDIT earnings forecast.
How were Editas Medicine's earnings last quarter?: Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.20. The company had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. Editas Medicine had a negative trailing twelve-month return on equity of 55.14% and a negative net margin of 1,065.39%. The firm's revenue for the quarter was down 54.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.78) EPS.
What ETFs hold Editas Medicine's stock?: ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX), Direxion Moonshot Innovators ETF (MOON), AXS Green Alpha ETF (NXTE) and WisdomTree BioRevolution Fund (WDNA).Global X Genomics & Biotechnology ETF (GNOM) and
What other stocks do shareholders of Editas Medicine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?: (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
What is Editas Medicine's stock symbol?: Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
Who are Editas Medicine's major shareholders?: Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.31%), State Street Corp (8.14%), Deep Track Capital LP (4.23%), Marshall Wace LLP (3.48%), Woodline Partners LP (3.37%) and Dimensional Fund Advisors LP (2.16%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.
How do I buy shares of Editas Medicine?: Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Editas Medicine's stock price today?: One share of EDIT stock can currently be purchased for approximately $6.93.
How much money does Editas Medicine make?: Editas Medicine (NASDAQ:EDIT) has a market capitalization of $565.70 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.
How many employees does Editas Medicine have?: The company employs 226 workers across the globe.
How can I contact Editas Medicine?: Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial